Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2005
10/06/2005WO2004069207A3 Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
10/06/2005WO2004044155A3 MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
10/06/2005WO2004041193A3 HUMAN TYPE II DIABETES GENE-Kv CHANNEL-INTERACTING PROTEIN (KChIP1) LOCATED ON CHROMOSOME 5
10/06/2005US20050222392 Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
10/06/2005US20050222388 Fusion protein of hiv regulatory/accessory proteins
10/06/2005US20050222387 Smac-peptides as therapeutics against cancer and autoimmune diseases
10/06/2005US20050222386 Biomolecule transduction motif sim-2-btm and the use thereof
10/06/2005US20050222385 Hybrid and tandem expression of neisserial proteins
10/06/2005US20050222102 Treatment of rhinitis with anticholinergics alone or in combination with antihistamines, phosphodiesterase 4 inhibitors, or corticosteroids
10/06/2005US20050222072 Potent mucosal immune response induced by modified immunomodulatory oligonucleotides
10/06/2005US20050222069 Optimization of immunomodulatory properties of genetic vaccines
10/06/2005US20050222060 Compositions and methods to initiate or enhance antibody and major-histocompatibility class I or class II-restricted t cell responses by using immunomodulatory, non-coding rna motifs
10/06/2005US20050222011 Selectin ligands
10/06/2005US20050221493 Recombinant virus production for the manufacturing of vaccines
10/06/2005US20050221489 Recombinant negative strand virus rna expression systems and vaccines
10/06/2005US20050221445 Useful as agents that inhibit virus infection of cells
10/06/2005US20050221440 Nucleic acid containing a reading frame with a first sequence encoding segments of the tumor associated antigen, PRAME (preferentially expressed antigen in melanoma); immunogenic; cluster sequences have affinity for a same Major Histocompatibility Complex receptor peptide binding cleft
10/06/2005US20050221439 Genes of an otitis media isolate of haemophilus influenzae
10/06/2005US20050221435 Biological material for preparing pharmaceutical compositions intended for treating mammals
10/06/2005US20050221421 Method of producing and using heat shock proteins
10/06/2005US20050221420 Nogo receptor homologues and their use
10/06/2005US20050221395 Methods and products based on oligomerization of stress proteins
10/06/2005US20050221388 Molecular interactions in hematopoietic cells
10/06/2005US20050221381 Method for isolating ligands
10/06/2005US20050221346 May be used to detect the presence of a cancer or to evaluate the prognosis of a known disease
10/06/2005US20050221344 Interferon-Like molecules and uses thereof
10/06/2005US20050221335 Reporter gene
10/06/2005US20050221330 Glial cell line-derived neurotrophic factor (GDNF); nervous system disorders, autonomic nervous system, shingles, asthma, irritable bowel, inflammatory bowel, constipation, headache, arthritis, spinal cord injury, chronic back pain, hypertension, mucositis, diabetes, fibromyalgia, and wound healing
10/06/2005US20050221317 Use of an epitope of vascular endothelial growth factor receptor kdr/flk-1
10/06/2005US20050221303 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
10/06/2005US20050221296 Comprises peptide for genotyping and detecting hepatitis viral infection; immunoassay; antigenic peptides of HCV immobilized on solid substrate
10/06/2005US20050221288 Variant tat proteins and methods for use thereof
10/06/2005US20050221285 Method for identifying or screening anti-viral agents
10/06/2005US20050221284 Heteropolymer complexes and methods for their use
10/06/2005US20050220894 Colostrum-based composition
10/06/2005US20050220883 Microparticles with adsorbed polypeptide-containing molecules
10/06/2005US20050220858 Codelivery to a cell of nucleic acid and assistor protein (antigen) where the nucleic acid encodes an antigenic protein or which shares an epitope(s) with the assistor protein; the nucleic acid is entrapped in liposome intravesicular space; assistor protein is on the liposome surface; synergistic
10/06/2005US20050220854 Apparatus and method for transdermal delivery of influenza vaccine
10/06/2005US20050220822 Methods for the prevention of malaria
10/06/2005US20050220820 Administering botulinum toxin to the patient, wherein excess levels of glandular secretion result in the conditions which are selected from seborrheic dermatitis, rhinophyma, seborrhea, seborrheic blepharitis and sebaceous cysts, whereby the excess levels of glandular secretions is reduced
10/06/2005US20050220819 Novel binding epitopes for helicobacter pylori and use thereof
10/06/2005US20050220818 Administration of therapeutic viruses
10/06/2005US20050220817 Stabilized soluble glycoprotein trimers
10/06/2005US20050220816 Mutant viral nucleic acids and vaccine containing same
10/06/2005US20050220814 Comprising a complex of saponin glycoside and a sterol in the form of helical micelles along with an antigen wherein the antigen is in admixture with, but not integrated within, said helical micelles; microfluidics; potentiation; immunostimulants; stability;nontoxic; veterinary medicine
10/06/2005US20050220813 Non-spreading pestivirus
10/06/2005US20050220812 Screening process
10/06/2005US20050220811 Identification of virulence associated regions rd1 and rd5 leading to improve vaccine of m. bovis bcg and m. microti
10/06/2005US20050220809 Nucleotide sequence coding for a tolc and a defined amino acid sequence
10/06/2005US20050220808 approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States Group A Streptococcus serotypes; do not elicit tissue cross-reactive antibodies
10/06/2005US20050220807 Methods of delivery of exogenous proteins to the cytosol and uses thereof
10/06/2005US20050220805 Polynucleotide sequence for Chalmydia pneumonia; therapy, prevention of Chlamydia infections ; vaccines
10/06/2005US20050220804 Increasing an immune response in an animal, comprising administering a compound (such as a carbohydrate, an antibiotic, a sugar, a protein, or an antibody) that binds a C-type lectin (but not the DEC-205 receptor) on the surface of a dendritic cell
10/06/2005US20050220803 Use of an organ-specific self-pathogen for treatment of a non-autoimmune disease of said organ
10/06/2005US20050220802 Vaccine and method for treatment of motor neurone diseases
10/06/2005US20050220800 Cytokines and cytokine receptors with reduced immunogenicity
10/06/2005US20050220799 Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
10/06/2005US20050220797 Prophylactic and therapeutic monoclonal antibodies
10/06/2005US20050220796 Compositions and methods for modulating DNA repair
10/06/2005US20050220795 Complementarity determining regions which bind to catalytic domain of aspartyl (asparaginyl) beta -hydroxylase; diagnosis and treatment of cancer; readily penetrates tumors, no side effects, less toxic
10/06/2005US20050220794 Growth/differentiation factor of the TGF-beta family
10/06/2005US20050220793 Anti-tissue factor antibodies and compositions
10/06/2005US20050220792 Selective inhibition of NF-kappaB activation by peptides designed to disrupt NEMO oligomerization
10/06/2005US20050220791 Novel of cytokine inhibitors
10/06/2005US20050220789 T cell immune response cDNA 7 (TIRC7) protein for use in treatment of organ transplantation rejection, tumor, autoimmune and/or allergic disorders
10/06/2005US20050220787 Naturally occuring IgM antibodies that bind to lymphocytes
10/06/2005US20050220786 Lyophilised preparation comprising antibodies against the efg receptor
10/06/2005US20050220785 Methods and formulations for reducing circulating antibodies
10/06/2005US20050220784 Quinazoline derivatives as medicaments
10/06/2005US20050220777 Selection of lactic acid bacteria enhancing the immune response against Streptococcus pneumoniae
10/06/2005US20050220767 Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
10/06/2005US20050220760 Novel immunotherapy
10/06/2005US20050220734 Therapy for melanin related afflictions
10/06/2005CA2564989A1 Reducing the risk of human and anti-human antibodies through v gene manipulation
10/06/2005CA2561264A1 Immunoglobulin variants outside the fc region
10/06/2005CA2561192A1 Cancerous disease modifying antibodies
10/06/2005CA2560919A1 Uses of anti-ctla-4 antibodies
10/06/2005CA2560903A1 Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis
10/06/2005CA2560864A1 Cytotoxicity mediation of cells evidencing surface expression of cd63
10/06/2005CA2560862A1 Cytotoxicity mediation of cells evidencing surface expression of mcsp
10/06/2005CA2560859A1 Cytotoxicity mediation of cells evidencing surface expression of cd44
10/06/2005CA2560696A1 Mutations of the pik3ca gene in human cancers
10/06/2005CA2560508A1 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
10/06/2005CA2559480A1 Methods and compositions for inhibition of metastasis
10/06/2005CA2557724A1 Methods and compositions for treating il-13 related pathologies
10/05/2005EP1582217A1 Method of obtaining conjugate vaccines and vaccine compositions containing same
10/05/2005EP1581812A2 Compositions and methods for diagnosing and treating colon cancers
10/05/2005EP1581794A2 Methods of diagnosing and treating cancer
10/05/2005EP1581759A2 Methods for treating taxol-induced sensory neuropathy
10/05/2005EP1581639A2 High pressure spray-dry of bioactive materials
10/05/2005EP1581638A1 P153 and p156 antigens for the immunodiagnosis of canine and human ehrlichioses and uses thereof
10/05/2005EP1581636A2 Methods using gene trapped stem cells for marking pathways of stem cell differentiation and making and isolating differentiated cells
10/05/2005EP1581629A2 Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
10/05/2005EP1581626A2 Culturing anaplasma
10/05/2005EP1581623A2 Trefoil domain-containing polypeptides and uses thereof
10/05/2005EP1581620A2 Antibodies that recognize hyperproliferative cells and methods of making and using same
10/05/2005EP1581616A2 Novel proteins and nucleic acids encoding same
10/05/2005EP1581614A2 Nucleotide sequences for gene regulation and methods of use thereof
10/05/2005EP1581560A1 Anti-idiotypic antibodies against factor viii inhibitor and uses thereof
10/05/2005EP1581256A2 Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen
1 ... 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 ... 1823